R&D News | pharmaphorum

News

Daiichi Sankyo partners Alteogen on subcutaneous Enhertu

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu.

News

Scientist in a laboratory with sequencer

NHS Wales partners with Illumina on genomics drive

Wales has extended a scheme to harness the power of genomics to improve cancer care and prevention via an alliance with gene-sequencing giant Illumina.

News

UK health data ecosystem 'is hampering research'

The UK is squandering the vast resource of NHS patient data because too many obstacles are being placed in front of researchers trying to tap into it – holding back medical advances.

News

Sarepta pulls plug on Duchenne exon-skipping drug

Sarepta Therapeutics has decided not to continue the development of vesleteplirsen, a follow-up to its Duchenne muscular dystrophy (DMD) therapy Exondys 51.

News

Novo sheds kidney drug licensed for $1.3bn a year ago

Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial.

News

Nick Green, president and CEO of Avid Bioservices

Avid Bioservices to go private in $1.1bn private equity deal

Anglo-US contract development and manufacturing organisation (CDMO) Avid Bioservices has agreed a deal to be acquired by private equity firms GHO Capital Partners and Ampersand Capital Part

Daiichi Sankyo partners Alteogen on subcutaneous Enhertu

NHS Wales partners with Illumina on genomics drive

UK health data ecosystem 'is hampering research'

Sarepta pulls plug on Duchenne exon-skipping drug

Novo sheds kidney drug licensed for $1.3bn a year ago

Avid Bioservices to go private in $1.1bn private equity deal

Inept digital interaction undermining pharma with clinicians

How to meet your physicians where they are online

News

Editor's Picks